CCL21 and cancer: Tumor progression, characterized by increased malignancy and reduced survival of cancer patients as a result of increased resistance to chemotherapy and metabolic adaptation to nutrient stress, can be associated with altered expression of drug efflux mediated by ABC, SLC, and APQ drug transporters and ATP‐dependent drug efflux pumps, leading to altered cellular accumulation of anticancer drugs [17].